GSK to license Empirico’s COPD candidate for $85M upfront

GSK said Tuesday it will spend $85 million upfront for an exclusive license to a Phase 1-stage small interfering RNA (siRNA) product being developed by Empirico to treat COPD. Empirico will oversee the ongoing Phase ...